139,227 Shares in Dynavax Technologies Corporation $DVAX Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new position in Dynavax Technologies Corporation (NASDAQ:DVAX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 139,227 shares of the biopharmaceutical company’s stock, valued at approximately $1,381,000. Y Intercept Hong Kong Ltd owned about 0.12% of Dynavax Technologies at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. purchased a new stake in Dynavax Technologies in the 1st quarter valued at about $312,000. GAMMA Investing LLC increased its stake in Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 3,627 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Dynavax Technologies in the 1st quarter valued at about $2,477,000. Woodline Partners LP increased its stake in Dynavax Technologies by 48.4% in the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock valued at $15,289,000 after buying an additional 384,288 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in Dynavax Technologies by 4.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 133,601 shares of the biopharmaceutical company’s stock valued at $1,325,000 after buying an additional 5,523 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Scott Dunseth Myers bought 3,800 shares of Dynavax Technologies stock in a transaction dated Friday, August 22nd. The stock was purchased at an average cost of $10.82 per share, with a total value of $41,116.00. Following the transaction, the director directly owned 35,004 shares of the company’s stock, valued at approximately $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.98% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on DVAX. Wall Street Zen upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dynavax Technologies has an average rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Stock Down 1.3%

Dynavax Technologies stock opened at $10.26 on Monday. Dynavax Technologies Corporation has a twelve month low of $9.20 and a twelve month high of $14.63. The firm has a 50 day moving average price of $10.00 and a 200-day moving average price of $10.29. The company has a market capitalization of $1.20 billion, a P/E ratio of -22.30 and a beta of 1.13. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The firm had revenue of $95.44 million during the quarter, compared to the consensus estimate of $87.55 million. As a group, equities analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.